Introduction
All current guidelines recommend an earlier initiation of antiretroviral therapy (ART) in HIV-infected individuals regardless of CD4 cell counts. 1 -3 The goals of ART include maximal viral suppression to reduce drug resistance and prevent virus transmission, 4 along with robust immune restoration to improve survival. 5, 6 Despite a better tolerability of newer antiretroviral drugs, a long exposure to the currently recommended antiretroviral drugs is associated with drug-induced toxicity and comorbidities. 1 One of the third recommended agents in triple-drug combinations is a protease inhibitor; protease inhibitors are associated with metabolic disorders, such as insulin resistance, diabetes and dyslipidaemia. Avoiding a long exposure to protease inhibitors when using a dual nucleoside reverse transcriptase inhibitor (NRTI) regimen could potentially reduce the long-term risk of non-AIDS-related morbidities such as cardiovascular diseases, which occur in up to 20% of HIV-infected patients. Furthermore in the absence of strategies to cure HIV, life-long suppressive therapy remains the rule. In this context, minimizing drug exposure without jeopardizing antiretroviral efficacy has become a field of clinical investigation. This appears even more important in the context of earlier ART initiation when HIV-infected patients initiate ART usually with a lower viral load (VL) and a higher CD4 cell count. It has been # The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2014; 69: 3356 -3359 doi:10.1093/jac/dku265 Advance Access publication 22 July 2014 well known since the early years of ART use that the two main drivers of the virological response following ART initiation in ARTnaive patients are the intensity of HIV replication and, to a lesser extent, the number of CD4 lymphocytes. 7 The question of whether an alternative to a triple-drug approach is possible in ART-naive patients treated at an early stage of HIV infection has become more relevant today in the context of universal ART. This pilot proof-of-concept study aimed to evaluate the efficacy of a dual NRTI strategy as first-line therapy in ART-naive patients with a low VL and a high CD4 cell count.
Patients and methods
This observational study aimed to evaluate the virological efficacy of a dual NRTI strategy in ART-naive patients followed at the HIV clinical unit of the Department of Infectious Diseases at Pitié-Salpêtrière University Hospital (Paris, France). All clinical data from HIV-infected patients who gave their consent were systematically recorded via an electronic file (NADIS) with direct access to the biological parameters and retrospectively assessed. From January 2008 to December 2012, we evaluated all ART-naive HIV-1-infected adult patients with a plasma HIV RNA level between 1000 and 30000 copies/mL and a CD4 cell count ≥300 cells/mm 3 who initiated ART with dual NRTIs consisting of tenofovir/emtricitabine or abacavir/lamivudine, in the context of a wild-type virus (determined by a genotypic resistance test) and with more than 6 weeks of follow-up. All patients were routinely monitored for HIV RNA level and CD4 cell count assessed at Day 0 (D0), Week (W) 4, W12, W24 and W48. Plasma HIV VL (pVL) was quantified using the CobasAmpliPrep/CobasTaqMan HIV-1 assay version 2.0 (Roche Diagnostics). The quantification of whole blood HIV DNA level was retrospectively performed on frozen samples at D0 and W24 using a realtime PCR method as previously described. 8 The study's primary endpoint was the proportion of patients with a pVL ,50 copies/mL by intention-to-treat (ITT) analysis at W24. Secondary endpoints included the rate of viral suppression with a pVL ,50 copies/mL at W48, time to viral suppression, the change in CD4 cells and the evolution of total HIV DNA in peripheral blood mononuclear cells (PBMCs) retrospectively assessed at W24. Treatment failure was defined as two consecutive plasma HIV-1 RNA values ≥50 copies/mL 2 weeks apart or as any modification or discontinuation of treatment. The exact CIs were calculated for the proportions of success at any time. Statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, USA). Continuous variables are expressed as medians and IQRs. Nominal variables are expressed as percentages.
Results
From a total of 1272 patients initiating ART between January 2008 and December 2012, 213 patients had baseline pre-ART values with CD4 cell counts .300 cells/mm 3 and an HIV RNA level between 1000 and 30 000 copies/mL; of these, 24 initiated dual NRTI therapy. All the criteria were fulfilled by 20 patients, who constituted our study population. This comprised 12 males and 8 females with a median age of 41 years (IQR 30 -51 years). The median time since HIV diagnosis was 25 months (IQR 8 -66 months). At baseline, the median CD4 cell count was 592 cells/mm 3 (IQR 405 -798 cells/mm 3 ), the plasma HIV RNA 10 395 copies/mL (IQR 4106 -16 566 copies/mL) and the total blood HIV DNA 464 copies/10 6 PBMCs (IQR 195 -1168 copies/ 10 6 PBMCs) The main viral subtypes were HIV-1 group M subtype B virus (n¼ 9/20) or circulating recombinant forms (CRFs) (5 CRF02 and 1 CRF22). One patient was coinfected with HIV and hepatitis B virus. Nineteen patients received dual therapy with tenofovir/ emtricitabine once daily and one patient received abacavir/lamivudine. All patients except one (Patient 14) , who moved to a foreign country, were followed for up to 48 weeks. All patients remained on the initial ART regimen during the follow-up.
By ITT missing equal failure analysis, the proportion of patients meeting the primary endpoint at W24 with a pVL ,50 copies/mL was 100% (n¼20/20, 95% CI 0.83-1.0) ( Table 1 ). The dynamics of HIV RNA following dual NRTI administration showed a median decrease in pVL of 22.2 log 10 (IQR 22 log 10 to 22.4 log 10 ) at W4 and 22.7 log 10 (IQR 22.4 log 10 to 22.8 log 10 ) at W12, when 88% of patients (n ¼ 16/18, 95% CI 0.65 -0.99) had a pVL ,50 copies/mL. The median time to viral suppression to ,50 copies/mL was 4 weeks (IQR 4 -12 weeks). At W48, the proportion of patients with an HIV RNA ,50 copies/mL was 95% (n¼ 18/19, 95% CI 0.74-0.99).
One patient (Patient 12) with transient poor compliance had a virological rebound with a pVL of 325 copies/mL at W48 after two values below 40 copies/mL from W4 to W24 and with no selection of mutations at the time of virological failure. The addition of a boosted protease inhibitor to the dual NRTI regimen led to rapid viral suppression.
A 
Discussion
This pilot study reported a total of 20 HIV-1-infected ART-naive patients with high CD4 cell counts and low viraemia treated with a dual NRTI regimen who achieved a maximal viral suppression (defined as a plasma HIV RNA level ,50 copies/mL), leading to a success rate of 100% (n¼20/20, 95% CI 0.83-1.0) at W24. The median time to viral suppression was 4 weeks. Importantly, all patients met the criteria for successful first-line therapy with a pVL ,400 copies/mL at W12 according to French guidelines 1 except for Patient 1, with the highest baseline VL, in whom the pVL was 69 copies/mL at W12. Not surprisingly, once viraemia was suppressed by 12 weeks of dual therapy, maximal virological suppression was maintained for up to 48 weeks for all compliant patients. One patient (Patient 12) self-reported a discontinuation of treatment 3 weeks before virological measurement. Meanwhile, in this patient, the efficacy of the regimen up to W24 and the absence of emtricitabine resistance were in favour of a loss of efficacy due to a transient discontinuation of therapy.
The patients who were selected initiated a dual NRTI strategy with a high CD4 cell count and a low VL and were at an early phase of HIV chronic infection with a median duration of HIV diagnosis of 2 years. None had been treated at the time of primary infection, thus excluding any potential decrease of VL under the pressure of the early immune response. The initiation of ART in patients with 'early' HIV infection with a high CD4 cell count and a low VL has become a common situation with the current recommendation of Dual NRTI regimen in early HIV chronic infection 3357 JAC extending HIV testing and an early initiation of therapy. 9 Indeed, in the most recent clinical randomized trials in ART-naive patients, there has been a progressive shift in the baseline characteristics of ART-naive patients, with earlier HIV infection, as attested to by a median baseline VL 4-4.5 log 10 , i.e. less than 50 000 copies/mL, and a median baseline CD4 cell count around 350 cells/mm 3 .
10,11
The well-established and universal goals for initiating ART are to reduce HIV-associated morbidity, prolong the duration and quality of survival, restore and preserve immunological function and prevent perinatal and behaviour-associated HIV transmission. 12 HIV suppression with ART may also decrease inflammation and immune activation, which are thought to contribute to the higher rates of comorbidities reported in HIV-infected patients. 13 Given the high potency of current antiretroviral drugs and the need to control life-long viral replication, and keeping in mind that lower drugs exposure should be of long-term benefit, there is a need to revisit antiretroviral strategies and investigate new approaches to individualize ART in patients with early HIV infection without any change in the objective of maximal rapid viral suppression. There have been studies investigating strategies such as protease inhibitor monotherapies, which were able to maintain virological suppression in over 85% of patients without any development of resistance, meaning no loss of treatment class efficacy in case of viral rebound 14 and no deleterious effect on HIV DNA. 15 In the days prior to the era of highly active antiretroviral therapy (HAART), in the context of patients with a CD4 cell count between 200 and 500 cells/mm 3 , a dual NRTI combination led to a mean decrease in HIV VL of 1.5 log 10 copies/mL after 24 weeks of the dual NRTI strategy. 16 However, this approach is not completely new. More than a decade ago, dual combination strategies, although statistically less potent than a triple-drug approach, were able to maintain virological suppression in a substantial number of patients. Interestingly, those patients had a VL in the lower range. 17 More recent data 18 have reported the efficacy of a dual NRTI regimen in 37 patients mostly in maintenance therapy, including eight taking a first-line regimen, with an overall success rate of 89% in patients with a high median pre-ART CD4 cell count and a low median HIV RNA VL of 3.9 log 10 copies/mL. In a retrospective analysis of 68 ART-naive patients receiving dual NRTI therapy, predictive factors for virological success, defined as a pVL ,400 copies/mL, were a pre-treatment CD4 cell count .150 cells/mm 3 , pre-treatment viraemia ,50 000 copies/mL and no previous NRTI exposure. 19 All except one patient received the dual combination of tenofovir/emtricitabine, an NRTI backbone universally recommended in ART initiation, which has been shown over the past decade to be a highly potent NRTI combination, with a higher efficacy, tolerability and resistance profile compared with first-generation NRTIs such as zidovudine or stavudine combined with lamivudine. 20, 21 Few data are currently available on the dynamics of total HIV DNA in blood following the initiation of ART except in primary infection, for which a DNA decrease of up to 0.78 log 10 /10 6 PBMCs was reported 48 weeks after initiation of HAART. 22 Importantly, we found a significant decrease in HIV DNA in the same range of what has been reported with triple drug therapy. 15, 23 Interestingly, five patients had a DNA value below the level of detection after 6 months of dual NRTI therapy. Overall, these results suggest that a dual NRTI strategy was not deleterious Seang et al.
with regard to HIV DNA and emphasizes the virological benefit of initiating treatment at an early stage of HIV infection. Our study has obvious limitations including its single-centre observational design, the limited size of the population and a profile of patients who wanted to be treated and were thus likely to be highly compliant. However, we think that these results deserve further investigation. Achieving maximal viral suppression with minimum drug exposure should be the goal of clinical studies in HIV over the next decade. A dual NRTI regimen could represent a potential option for long-term virological control in HIV-1 ARTnaive patients with a low pVL and a high immunity, but further investigations are needed to validate such a strategy.
